U.S. markets closed

Biocept, Inc. (BIOC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
5.36-0.12 (-2.19%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close5.48
Open5.54
Bid5.31 x 1000
Ask5.33 x 900
Day's Range5.30 - 5.74
52 Week Range2.10 - 13.00
Volume461,349
Avg. Volume652,288
Market Cap71.806M
Beta (5Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)-2.37
Earnings DateMar 23, 2021 - Mar 29, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    Biocept Issues Letter to Stockholders

    Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient outcomes, announces that President and CEO Michael W. Nall has issued the following letter to stockholders:

  • Biocept to Present at H.C. Wainwright Virtual BioConnect Conference
    PR Newswire

    Biocept to Present at H.C. Wainwright Virtual BioConnect Conference

    Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that President and CEO Michael Nall will present at the H.C. Wainwright Virtual BioConnect Conference being held January 11-14, 2021. The presentation can be accessed on the Investor Relations section of the Biocept website beginning on January 11, 2021 at 6:00 a.m. Eastern time.

  • Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    PR Newswire

    Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, today announced that it has granted inducement stock options to purchase an aggregate of 83,120 shares of its common stock to 14 new employees. These inducement stock options have a grant date of December 31, 2020, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).